乙肝免疫球蛋白撤药在乙肝病毒单感染肝移植受者中的安全性:意大利多中心前瞻性研究
意大利多中心前瞻性研究纳入222例长期使用第三代核苷(酸)类似物联合乙肝免疫球蛋白(HBIG)的乙肝病毒单感染肝移植受者,撤除HBIG后中位随访24个月。HBsAg再现率为5.4%,累积1年、2年、3年复发率分别为4.08%、5.36%、6.89%;HBsAg水平很低,HBV-DNA持续检测不到,肝功能正常,未观察到乙肝相关肝炎或肝细胞癌。结论认为撤除HBIG是安全的。
要点
- 长期HBIG联合第三代核苷(酸)类似物的乙肝单感染肝移植受者撤除HBIG后HBsAg再现率低。
- 撤药后HBsAg再现者HBV-DNA持续检测不到,肝功能正常,无乙肝相关肝炎或肝细胞癌。
- 撤除HBIG的安全性不受移植时是否存在肝细胞癌影响。
核心结论
- 在长期使用HBIG联合第三代核苷(酸)类似物的乙肝病毒单感染肝移植受者中,撤除HBIG是安全的。
研究设计与样本
- 多中心、前瞻性、意大利队列研究,纳入222例长期使用第三代核苷(酸)类似物联合HBIG且遵循INSIGHT-B方案的肝移植受者,撤药后随访评估HBV再激活风险。
主要发现
- 222例受者在肝移植后11.6年(IQR 6.7-17.0)撤除HBIG,中位随访24个月,12例(5.4%)出现HBsAg再现。
- 撤药后HBsAg累积1年、2年、3年再现率分别为4.08%、5.36%、6.89%。
- HBsAg血清水平在整个观察期(中位9个月,范围3-20)保持很低,4例在检测阈值附近波动。
- 所有病例HBV-DNA持续检测不到,肝功能检查保持正常范围,未观察到乙肝相关肝炎或肝细胞癌。
- 未发现基线患者特征(包括移植时存在肝细胞癌)与HBIG撤药后HBsAg再现风险显著相关。
临床怎么用
- 对于长期使用第三代核苷(酸)类似物联合HBIG的乙肝病毒单感染肝移植受者,可考虑安全撤除HBIG。
- 撤除HBIG后需监测HBsAg再现,但再现者HBV-DNA持续检测不到且肝功能正常,未见乙肝相关肝炎或肝细胞癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Despite recommendations from scientific societies that hepatitis B immunoglobulin (HBIG) can be safely discontinued, centres across Europe continue to use the combination nucleoside analogues (NAs) plus HBIG for long-term prophylaxis against hepatitis B virus (HBV) recurrence after liver transplant (LT). The aim of this study was to evaluate the safety of HBIG withdrawal in a cohort of LT recipients on long-term HBIG+NAs. METHODS: All patients under third-generation NAs + HBIG and who adhered to the INSIGHT-B protocol were followed up after HBIG withdrawal, in a multicentre, prospective, Italian cohort study, to evaluate the risk of HBV reactivation. The probability of HBsAg reappearance after HBIG withdrawal, stratified by presence of HCC at LT, was estimated through Kaplan-Meier curves and Log-rank tests. RESULTS: Between February 2021 and January 2024, 222 liver transplant (LT) recipients withdrew HBIG 11.6 (IQR 6.7-17.0) years after LT and were followed up for a median time of 24 months. After HBIG withdrawal, Hepatitis B surface antigen (HBsAg) reappearance was observed in 12 patients (5.4%) with a cumulative 1-, 2- and 3-year recurrence rate of 4.08%, 5.36% and 6.89% respectively. HBsAg serum levels remained very low over the entire period of observation (median 9 months, range 3-20), and in four cases fluctuated around the detectability threshold. In all cases, HBV-DNA persisted undetectable, liver function tests (LFTs) remained within the normal range, and neither HBV-related hepatitis nor HCC were observed. No baseline patients' features were found to be significantly associated with the likelihood of HBsAg reappearance after HBIG withdrawal, including the presence of HCC at transplantation. CONCLUSIONS: HBIG could be safely withdrawn in HBV mono-infected LT recipients on long-term combination HBIG plus third generation NAs.
引用
- Viganò R, Loglio A, Dibenedetto C, et al. Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study. Aliment Pharmacol Ther. 2025. PMID: 40873133. doi:10.1111/apt.70348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。